COO

Cooper Companies Inc

Add to Watchlist

Advanced Chart

68.000

-0.17(-0.249%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

68.400

Open

67.680

VWAP

67.66

Vol

2.88M

Mkt Cap

13.52B

Low

66.840

Amount

194.88M

EV/EBITDA(TTM)

14.29

Total Shares

199.12M

15.87B

EV/OCF(TTM)

19.44

P/S(TTM)

3.37

The Cooper Companies, Inc. is a global medical device company. The Company operates in two business units: CooperVision and CooperSurgical. CooperVision segment is involved in the contact lens industry. CooperSurgical segment is involved in the fertility and women's health care market through its diversified portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. CooperVision’s products include MyDay daily disposable, MyDay daily disposable toric, MyDay Energys, MyDay multifocal, Biofinity & Biofinity XR, Biofinity Energys. CooperSurgical’s portfolio includes INSORB, Lone Star, and the Doppler Blood Flow Monitor. It also offers a suite of single-use cordless surgical retractors with an integrated multi-light-emitting diode (LED) light source and dual smoke evacuation channels, and single-use surgical suction devices with an integrated, cordless radial LED light source.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

FY2026Q1

FY2025Q4

1.06B

+5.79%

1.050

+9.33%

1.02B

+6.21%

1.010

+9.76%

1.06B

+4.41%

1.114

+7.15%

Estimates Revision

The market is revising Downward the revenue expectations for The Cooper Companies, Inc. (COO) for FY2025, with the revenue forecasts being adjusted by -0.67% over the past three months. During the same period, the stock price has changed by -2.19%.

Revenue Estimates for FY2025

Revise Downward

-0.67%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.73%

In Past 3 Month

Stock Price

Go Down

-2.19%

In Past 3 Month

12 Analyst Rating

21.79% Upside

Wall Street analysts forecast COO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COO is 82.82 USD with a low forecast of 66.00 USD and a high forecast of 96.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

4 Hold

0 Sell

Moderate Buy

21.79% Upside

Current: 68.000

Low

66.00

Averages

82.82

High

96.00

21.79% Upside

Current: 68.000

Low

66.00

Averages

82.82

High

96.00

Citi

Joanne Wuensch

Buy -> Neutral

downgrade

$97 -> $72

2025-08-28

Reason

Citi

Joanne Wuensch

Price Target

$97 -> $72

2025-08-28

downgrade

Buy -> Neutral

Reason

Citi analyst Joanne Wuensch downgraded Cooper Companies to Neutral from Buy with a price target of $72, down from $97. The firm views the company's fiscal Q3 report as disappointing and cites execution uncertainty for the downgrade. Citi sees less visibility now for Cooper.

Piper Sandler

Overweight

downgrade

$105 -> $83

2025-08-28

Reason

Piper Sandler

Price Target

$105 -> $83

2025-08-28

downgrade

Overweight

Reason

Piper Sandler lowered the firm's price target on Cooper Companies to $83 from $105 and keeps an Overweight rating on the shares. The firm says the company's streak of disappointing CVI results continued at +2% organic vs. guidance/expectations of +5%, the weakest performance for the segment since the Great Recession and the primary factor driving shares down 12% after hours from what were already depressed valuation levels. If not for shares already being under pressure and significant value unlocking potential available through a handful of avenues, Piper says it would likely be reconsidering its rating today.

Stifel

Buy

downgrade

$90 -> $85

2025-08-28

Reason

Stifel

Price Target

$90 -> $85

2025-08-28

downgrade

Buy

Reason

Stifel lowered the firm's price target on Cooper Companies to $85 from $90 and keeps a Buy rating on the shares. FY25 CVI revenue guidance was stepped down for the second consecutive quarter and CSI was brought down as well, but by a more modest amount, says the analyst, who calls the revision "disappointing." However, management expressed confidence they will recapture contact lens share gains in 2026, the analyst noted.

Morgan Stanley

Patrick Wood

Equal Weight

downgrade

$84 -> $76

2025-08-28

Reason

Morgan Stanley

Patrick Wood

Price Target

$84 -> $76

2025-08-28

downgrade

Equal Weight

Reason

Morgan Stanley analyst Patrick Wood lowered the firm's price target on Cooper Companies to $76 from $84 and keeps an Equal Weight rating on the shares. Cooper "very clearly had a difficult Q3 print," with CVI organic growth of 2% "well shy" of buyside expectations of 5% and the explanation on the call of MyDay strength cannibalizing Clariti being "a little confusing," the analyst tells investors. CVI shortfalls, plus challenges in CSI, leave Cooper in "a tricky spot despite the stock having derated significantly over the last year," adds the analyst, who views the stock as "still very much in a show-me situation."

BNP Paribas Exane

Neutral -> Outperform

upgrade

$92

2025-07-22

Reason

BNP Paribas Exane

Price Target

$92

2025-07-22

upgrade

Neutral -> Outperform

Reason

BNP Paribas Exane upgraded Cooper Companies to Outperform from Neutral with a $92 price target.

Mizuho

Outperform -> NULL

downgrade

$105 -> $90

2025-07-16

Reason

Mizuho

Price Target

$105 -> $90

2025-07-16

downgrade

Outperform -> NULL

Reason

Mizuho lowered the firm's price target on Cooper Companies to $90 from $105 and keeps an Outperform rating on the shares. The firm adjusted price targets in medical devices and diagnostics ahead of the Q2 reports.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Cooper Companies Inc (COO.O) is 15.72, compared to its 5-year average forward P/E of 25.21. For a more detailed relative valuation and DCF analysis to assess Cooper Companies Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Strongly Undervalued

5Y Average PE

25.21

Current PE

15.72

Overvalued PE

29.85

Undervalued PE

20.56

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

18.79

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

21.59

Undervalued EV/EBITDA

15.99

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

5.10

Current PS

0.00

Overvalued PS

6.09

Undervalued PS

4.10